gemcitabine doublets more effective than monotherapy for pancreatic cancer

Inpharma 1610 - 20 Oct 2007 ■ Gemcitabine-based doublets are more effective than gemcitabine alone for advanced and metastatic pancreatic cancer, according to researchers from France and Italy. They performed a systematic review and meta-analysis of 23 controlled phase II–III trials involving 5886 such patients who were randomised to receive either gemcitabine alone (n = 2954) or gemcitabine-based doublets. * In patients treated with gemcitabine-based doublets, the risk of death was significantly reduced by 8%, 4%, and 3% at 6, 12 and 18 months, respectively, compared with those who received gemcitabine alone. * gemcitabine in combination with one of the following; capecitabine, cisplatin, erlotinib, etalocib, exatecan, fluorouracil, gastrin-17 vaccine, irinotecan, marimastat, oxaliplatin, pemetrexed, tegafur/uracil, tipifarnib or ukrain, or with a combination of cisplatin, epirubicin and fluorouracil Banu E, et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs and Aging 24: 865-879, No. 10, 2007 801055267 1 Inpharma 20 Oct 2007 No. 1610 1173-8324/10/1610-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 09-Dec-2016

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: Gemcitabine doublets more effective than monotherapy for pancreatic cancer

Inpharma 1610 - 20 Oct 2007

■ Gemcitabine-based doublets are more effectivethan gemcitabine alone for advanced and metastaticpancreatic cancer, according to researchers fromFrance and Italy. They performed a systematic reviewand meta-analysis of 23 controlled phase II–III trialsinvolving 5886 such patients who were randomised toreceive either gemcitabine alone (n = 2954) orgemcitabine-based doublets.* In patients treated withgemcitabine-based doublets, the risk of death wassignificantly reduced by 8%, 4%, and 3% at 6, 12 and18 months, respectively, compared with those whoreceived gemcitabine alone.* gemcitabine in combination with one of the following;capecitabine, cisplatin, erlotinib, etalocib, exatecan, fluorouracil,gastrin-17 vaccine, irinotecan, marimastat, oxaliplatin,pemetrexed, tegafur/uracil, tipifarnib or ukrain, or with acombination of cisplatin, epirubicin and fluorouracil

Banu E, et al. Meta-analysis of randomised trials comparing gemcitabine-baseddoublets versus gemcitabine alone in patients with advanced and metastaticpancreatic cancer. Drugs and Aging 24: 865-879, No. 10, 2007 801055267

Folfirinox versus gemcitabine 2003

Key Study Results in PI Monotherapy

GÉOMÉTRIE MOLÉCULAIRE. La forme dune molécule dépendant du montant de doublets liants et de doublets non liants (libres) délectrons sur sa couche de valence

Monotherapy Versus Combination Therapy

NEW ZEALAND DATA SHEET - MedsafeGemcitabine hydrochloride 43.3 mg/mL (equivalent to gemcitabine 38 mg/mL). Each vial contains gemcitabine hydrochloride. DBL Gemcitabine Injection contains

NorthStar Rx LLC GEMCITABINE- gemcitabine hydrochloride

Gemcitabine Plus Cisplatin for Advanced Biliary Tract

Aerosol Gemcitabine after Amputation Inhibits …downloads.hindawi.com/journals/sarcoma/2018/3143096.pdfAerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but

Ipilimumab Monotherapy Study

(GEMCITABINE HCl) FOR INJECTION · (GEMCITABINE HCl) FOR INJECTION ... Gemcitabine plasma protein binding is negligible. The pharmacokinetics of gemcitabine were examined in 353 patients,

Phenomenology of the Inert (2+1) and (4+2) Higgs Doublet ...an even number of doublets, we then extend this model into a model with four inert doublets plus two Higgs doublets (I(4+2)HDM)

Dicoumarol enhances gemcitabine-induced cytotoxicity in ......Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells Benjaporn Buranrat,